Alirocumab SAR236553

DRUG2 trials

Sponsors

Sanofi

Conditions

Acute Coronary SyndromeHypercholesterolaemiaHypercholesterolemia

Phase 3

Usability Study of the Commercial Auto-injector Device and the New Auto-injector Device (SYDNEY) in Patients With High or Very High CV Risk With Hypercholesterolemia Not Adequately Controlled With Their Lipid-Modifying Therapy

CompletedNCT03415178

SanofiHypercholesterolaemia

Start: 2018-03-29End: 2018-08-09Updated: 2019-09-09

Phase 4

Evaluation of Effect of Alirocumab on Coronary Atheroma Volume in Japanese Patients Hospitalized for Acute Coronary Syndrome With Hypercholesterolemia

CompletedNCT02984982

SanofiAcute Coronary Syndrome, Hypercholesterolemia

Start: 2016-11-15End: 2018-07-27Updated: 2019-09-09

Related Papers

The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device.

2019-12-246 citations

Effect of alirocumab on coronary atheroma volume in Japanese patients with acute coronary syndromes and hypercholesterolemia not adequately controlled with statins: ODYSSEY J-IVUS rationale and design.

2018-03-307 citations